These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 34873868)

  • 1. Infectious complications of immune checkpoint inhibitors in solid organ malignancies.
    Ross JA; Komoda K; Pal S; Dickter J; Salgia R; Dadwal S
    Cancer Med; 2022 Jan; 11(1):21-27. PubMed ID: 34873868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Kim YJ; Lee M; Kim EH; Lee S; Park S; Hong MH; Shin SJ; Jung I; Lee CK; Lee CS
    Cancer Lett; 2024 Aug; 596():216998. PubMed ID: 38830470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis.
    Paderi A; Gambale E; Botteri C; Giorgione R; Lavacchi D; Brugia M; Mazzoni F; Giommoni E; Bormioli S; Amedei A; Pillozzi S; Matucci Cerinic M; Antonuzzo L
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
    Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
    Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
    Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
    Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications in patients treated with immune checkpoint inhibitors.
    Karam JD; Noel N; Voisin AL; Lanoy E; Michot JM; Lambotte O
    Eur J Cancer; 2020 Dec; 141():137-142. PubMed ID: 33137589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy.
    Kanjanapan Y; Yip D
    Cancer Med; 2020 Dec; 9(23):9027-9035. PubMed ID: 33159505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
    Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
    Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.
    Huang Y; Soon YY; Aminkeng F; Tay SH; Ang Y; Kee ACL; Goh BC; Wong ASC; Soo RA
    Int J Cancer; 2022 Feb; 150(4):636-644. PubMed ID: 34562273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.